Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + gemcitabine/oxaliplatin followed by camrelizumab + fluzoparib or apatinib in advanced biliary tract carcinoma
ChiCTR2200065621Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer (2 cohorts), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: 6-month progression-free survival rate. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2200065621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065621.